Ozempic, Wegovy might lower Alzheimer's risk in Type 2 diabetics
People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared to patients taking seven other diabetes drugs, researchers reported.
Ozempic may significantly lower the risk of Alzheimer’s disease — here’s how
Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.
Drug in Ozempic may also help reduce risk of Alzheimer’s
A common diabetes and weight-loss drug may also reduce the risk of Alzheimer’s disease, according to a new study. American researchers have found that, when compared to seven other anti-diabetic drugs, semaglutide may lower the risk of the most prevalent form of dementia in people with type 2 diabetes (T2D).
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.
Novo’s Ozempic Linked to Reduced Alzheimer’s Diagnoses
Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.
Ozempic linked to lower Alzheimer’s risk in people with Type 2 diabetes
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.
Ozempic can even cut the risk of Alzheimer’s disease, study says
Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of Alzheimer’s disease.
Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
Semaglutide might help ward off Alzheimer’s disease, a new study says. Type 2 diabetics taking the drug had a lower risk of Alzheimer’s compared to patients on other diabetes
Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study
In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.
Pharmaceutical Technology1h
Pharmacists “desperation” by Novo Nordisk over semaglutide copycat block
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...
Here’s How Quickly Semaglutide Actually Works If You're Trying To Lose Weight
Weight loss medications like Ozempic can help you lose weight as early as one week. A doctor explains how fast semaglutide ...
How Fast Does Semaglutide Work? Here’s When You’ll Start To See Weight Loss Changes, According To A Doctor
Trying to lose weight quickly can feel like an uphill battle, but weight loss medications like Ozempic or Wegovy can speed up ...
healthday1h
Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses ...
Medscape3h
Oral Semaglutide May Boost Liver Health in Type 2 Diabetes
Oral semaglutide improved liver health, diabetes status, and lipid profile in patients with MASLD and T2D, with weight loss ...
News Medical on MSN5h
Semaglutide may lower Alzheimer's risk in type 2 diabetes patients
Researchers at the Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk ...
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...
Medscape2h
More Evidence Ties Semaglutide to Reduced Alzheimer’s Risk
The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.